AstraZeneca PLc (AZN) Tuesday announced results from the phase III head to head trial, PLATO – a study of platelet inhibition and patient outcomes – which demonstrate that ticagrelor (BrilintaTM) has achieved greater efficacy in the primary endpoint, reduction of cardiovascular events over clopidogrel (9.8% vs 11.7% at 12 months; 16% RRR; 95% CI, 0.77 [...]